Halozyme Therapeutics, Inc. (NASDAQ:HALO) Receives Consensus Rating of “Moderate Buy” from Analysts

Halozyme Therapeutics, Inc. (NASDAQ:HALO) has received an average rating of “Moderate Buy” from the thirteen research firms that are covering the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, four have assigned a hold recommendation and eight have assigned a buy recommendation to the company. The average 12-month target price among analysts that have issued a report on the stock in the last year is $81.60.

A number of research firms have commented on HALO. Weiss Ratings raised shares of Halozyme Therapeutics from a “hold (c)” rating to a “buy (b-)” rating in a report on Tuesday, May 12th. UBS Group reissued a “buy” rating and issued a $90.00 price target on shares of Halozyme Therapeutics in a research note on Wednesday, June 3rd. Benchmark restated a “buy” rating on shares of Halozyme Therapeutics in a research report on Wednesday, June 3rd. Morgan Stanley decreased their price objective on Halozyme Therapeutics from $96.00 to $93.00 and set an “overweight” rating for the company in a research note on Tuesday, May 12th. Finally, HC Wainwright reiterated a “buy” rating on shares of Halozyme Therapeutics in a report on Tuesday, June 16th.

Insiders Place Their Bets

In related news, CEO Helen Torley sold 20,000 shares of Halozyme Therapeutics stock in a transaction that occurred on Tuesday, May 12th. The shares were sold at an average price of $71.75, for a total transaction of $1,435,000.00. Following the transaction, the chief executive officer owned 767,780 shares of the company’s stock, valued at $55,088,215. This trade represents a 2.54% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Mahesh Krishnan sold 7,304 shares of the business’s stock in a transaction that occurred on Monday, June 29th. The shares were sold at an average price of $75.00, for a total transaction of $547,800.00. Following the transaction, the director owned 14,462 shares of the company’s stock, valued at approximately $1,084,650. This represents a 33.56% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 74,102 shares of company stock worth $5,205,798. Insiders own 2.50% of the company’s stock.

Institutional Investors Weigh In On Halozyme Therapeutics

Hedge funds have recently bought and sold shares of the company. Measured Wealth Private Client Group LLC raised its stake in Halozyme Therapeutics by 51.5% during the 4th quarter. Measured Wealth Private Client Group LLC now owns 365 shares of the biopharmaceutical company’s stock worth $25,000 after buying an additional 124 shares during the period. Abel Hall LLC grew its stake in Halozyme Therapeutics by 4.2% in the fourth quarter. Abel Hall LLC now owns 3,216 shares of the biopharmaceutical company’s stock valued at $216,000 after acquiring an additional 129 shares during the period. StoneX Group Inc. grew its stake in Halozyme Therapeutics by 3.8% in the fourth quarter. StoneX Group Inc. now owns 3,650 shares of the biopharmaceutical company’s stock valued at $246,000 after acquiring an additional 132 shares during the period. Moran Wealth Management LLC increased its holdings in shares of Halozyme Therapeutics by 0.4% in the fourth quarter. Moran Wealth Management LLC now owns 35,596 shares of the biopharmaceutical company’s stock worth $2,396,000 after acquiring an additional 151 shares in the last quarter. Finally, Twin Capital Management Inc. raised its position in shares of Halozyme Therapeutics by 1.4% during the first quarter. Twin Capital Management Inc. now owns 11,422 shares of the biopharmaceutical company’s stock worth $738,000 after purchasing an additional 161 shares during the period. 97.79% of the stock is currently owned by institutional investors and hedge funds.

Halozyme Therapeutics Stock Performance

Shares of NASDAQ:HALO opened at $77.54 on Friday. The company has a current ratio of 2.76, a quick ratio of 2.33 and a debt-to-equity ratio of 8.81. Halozyme Therapeutics has a 1-year low of $55.64 and a 1-year high of $82.26. The stock has a market capitalization of $9.20 billion, a P/E ratio of 27.89, a P/E/G ratio of 0.31 and a beta of 0.84. The business has a 50-day moving average price of $71.76 and a two-hundred day moving average price of $70.14.

Halozyme Therapeutics (NASDAQ:HALO) last issued its earnings results on Monday, May 11th. The biopharmaceutical company reported $1.60 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.54 by $0.06. The company had revenue of $376.71 million for the quarter, compared to analyst estimates of $358.60 million. Halozyme Therapeutics had a net margin of 23.13% and a return on equity of 187.91%. The company’s revenue for the quarter was up 42.2% on a year-over-year basis. During the same quarter last year, the firm earned $1.11 EPS. Halozyme Therapeutics has set its FY 2026 guidance at 7.750-8.250 EPS. Equities analysts predict that Halozyme Therapeutics will post 7.54 earnings per share for the current year.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.